$OTLC
Oncotelic Therapeutics, Inc.

2015 Q1 Form 10-K Financial Statement

#000119312515111261 Filed on March 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.110M $5.240M $980.0K
YoY Change -10.48% 10.55% 4.26%
% of Gross Profit
Research & Development $1.669M $7.408M $1.120M
YoY Change 20.33% 103.74% 45.45%
% of Gross Profit
Depreciation & Amortization $5.000K $16.00K $30.00K
YoY Change 25.0% 33.33% -40.0%
% of Gross Profit
Operating Expenses $2.777M $12.65M $2.100M
YoY Change 5.67% 51.04% 22.81%
Operating Profit -$2.777M -$12.65M
YoY Change 5.67% 52.78%
Interest Expense $0.00 $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.000K -$3.000K $0.00
YoY Change -166.67% 200.0% -100.0%
Pretax Income -$2.770M -$12.65M -$2.100M
YoY Change 5.32% 52.78% 25.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.772M -$12.65M -$2.100M
YoY Change 5.4% 52.8% 25.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.75 -$0.48
COMMON SHARES
Basic Shares Outstanding 26.54M shares 3.134M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.74M $30.03M $7.010M
YoY Change 44.46% 328.39% 41.62%
Cash & Equivalents $35.74M $30.03M $7.010M
Short-Term Investments
Other Short-Term Assets $760.0K $320.0K $67.00K
YoY Change 1753.66% 100.0% -52.82%
Inventory
Prepaid Expenses $755.0K $93.00K
Receivables
Other Receivables
Total Short-Term Assets $36.49M $30.35M $7.165M
YoY Change 45.12% 323.29% 36.66%
LONG-TERM ASSETS
Property, Plant & Equipment $32.00K $40.00K $36.00K
YoY Change 0.0% 0.0% 176.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $30.00K
YoY Change
Total Long-Term Assets $65.00K $70.00K $129.0K
YoY Change -36.27% -41.67% -36.76%
TOTAL ASSETS
Total Short-Term Assets $36.49M $30.35M $7.165M
Total Long-Term Assets $65.00K $70.00K $129.0K
Total Assets $36.56M $30.42M $7.294M
YoY Change 44.8% 317.28% 33.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $189.0K $340.0K $476.0K
YoY Change -56.25% -29.17% 14.42%
Accrued Expenses $840.0K $1.080M $780.0K
YoY Change -12.5% 38.46% 59.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.029M $1.420M $1.251M
YoY Change -26.24% 13.6% 38.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.029M $1.420M $1.251M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.030M $1.420M $1.250M
YoY Change -26.43% 13.6% 38.89%
SHAREHOLDERS EQUITY
Retained Earnings -$253.9M -$238.5M
YoY Change 5.3% 5.8%
Common Stock $289.5M $244.6M
YoY Change 9.23% 6.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $35.53M $29.00M $6.043M
YoY Change
Total Liabilities & Shareholders Equity $36.56M $30.42M $7.294M
YoY Change 44.8% 317.28% 33.91%

Cashflow Statement

Concept 2015 Q1 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$2.772M -$12.65M -$2.100M
YoY Change 5.4% 52.8% 25.0%
Depreciation, Depletion And Amortization $5.000K $16.00K $30.00K
YoY Change 25.0% 33.33% -40.0%
Cash From Operating Activities -$3.500M -$12.15M -$2.130M
YoY Change 33.38% 73.55% 13.3%
INVESTING ACTIVITIES
Capital Expenditures $17.00K $40.00K
YoY Change -57.5% 300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$40.00K
YoY Change -42.86% 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.207M $25.68M
YoY Change -15.22% 1226.55%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.210M 35.19M 400.0K
YoY Change -54.75% 286.92% -24.53%
NET CHANGE
Cash From Operating Activities -3.500M -12.15M -2.130M
Cash From Investing Activities -20.00K -40.00K
Cash From Financing Activities 9.210M 35.19M 400.0K
Net Change In Cash 5.710M 23.02M -1.770M
YoY Change -67.79% 1018.02% 30.15%
FREE CASH FLOW
Cash From Operating Activities -$3.500M -$12.15M -$2.130M
Capital Expenditures $17.00K $40.00K
Free Cash Flow -$12.17M -$2.170M
YoY Change 72.8% 14.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.75
CY2014Q1 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.90
CY2014Q2 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0499 pure
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1377412 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
53551000
CY2011Q4 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
1226000
CY2011Q4 us-gaap Restructuring Reserve
RestructuringReserve
653000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
8797000
CY2011Q4 us-gaap Cash
Cash
9972000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.73
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
143000 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
4546000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
673880
CY2012Q4 us-gaap Cash
Cash
4946000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5586000 shares
CY2009Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1360000
CY2009Q4 oxgn Recorded Capital Loss Carryforward
RecordedCapitalLossCarryforward
4000000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.06
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
83000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5586000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.54
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5178000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192000 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
78581000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268000
CY2013Q4 us-gaap Restructuring Reserve
RestructuringReserve
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1251000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
476000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238508000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244495000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
6043000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
342000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7294000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1406000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
154000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
748036
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
116000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
78581000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93000
CY2013Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1360000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
434000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
304000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
74533000
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2171000
CY2013Q4 us-gaap Assets
Assets
7294000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Cash
Cash
7005000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
7165000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
83000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93000
CY2013Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
317000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
565000 shares
CY2013Q4 oxgn Other Miscellaneous Accrued Liabilities Current
OtherMiscellaneousAccruedLiabilitiesCurrent
188000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20705000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20705000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.63
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
244000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.51
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.24
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1054625 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7445000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.73
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
672000 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82459000
CY2014Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1689000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
242000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1419000
CY2014Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
21000
CY2014Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
353000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
207000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
335000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251155000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
221000
CY2014Q4 us-gaap Contractual Obligation
ContractualObligation
4991000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
279952000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
29004000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
207000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
959000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
215000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30423000
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1500000
CY2014Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
258000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
179000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1092908
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
209000
CY2014Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
136000
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
202000
CY2014Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
2555000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
841000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
515000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
82459000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
667000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
279000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
79194000
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2301000
CY2014Q4 us-gaap Assets
Assets
30423000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Cash
Cash
30031000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
30353000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
297000
CY2014Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
1500000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
318000
CY2014Q4 oxgn Clinical Development And Related Commitments
ClinicalDevelopmentAndRelatedCommitments
4032000
CY2014Q4 oxgn Purchase Commitment Amount Due
PurchaseCommitmentAmountDue
4803000
CY2014Q4 oxgn Clinical Development And Related Commitments Due In Fifth Year And Thereafter
ClinicalDevelopmentAndRelatedCommitmentsDueInFifthYearAndThereafter
24000
CY2014Q4 oxgn Purchase Commitment Estimated And Accrued
PurchaseCommitmentEstimatedAndAccrued
92000
CY2014Q4 oxgn Clinical Development And Related Commitments Due In Second Year
ClinicalDevelopmentAndRelatedCommitmentsDueInSecondYear
1480000
CY2014Q4 oxgn Clinical Development And Related Commitments Obligation Due In Fourth Year
ClinicalDevelopmentAndRelatedCommitmentsObligationDueInFourthYear
37000
CY2014Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
36000
CY2014Q4 oxgn Clinical Development And Related Commitments Due In Next Twelve Months
ClinicalDevelopmentAndRelatedCommitmentsDueInNextTwelveMonths
2353000
CY2014Q4 oxgn Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Related Party
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRelatedParty
147145 shares
CY2014Q4 oxgn Other Miscellaneous Accrued Liabilities Current
OtherMiscellaneousAccruedLiabilitiesCurrent
7000
CY2014Q4 oxgn Future Purchase Commitment
FuturePurchaseCommitment
2353000
CY2014Q4 oxgn Clinical Development And Related Commitments Due In Third Year
ClinicalDevelopmentAndRelatedCommitmentsDueInThirdYear
138000
CY2014Q4 oxgn Operating Lease Future Minimum Payments Due After Fourth Full Fiscal Year
OperatingLeaseFutureMinimumPaymentsDueAfterFourthFullFiscalYear
112000
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
12000000
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10860000
CY2014Q1 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2014Q2 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
16000000
CY2014Q2 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
14822000
CY2014Q2 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y3M18D
CY2014Q2 oxgn Increase In Threshold Limit Percentage On Warrants Owned
IncreaseInThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5000000
CY2013Q2 oxgn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4192000
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5800000
CY2013Q3 oxgn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4905000
CY2011 us-gaap Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
80000
CY2011 us-gaap Payments For Restructuring
PaymentsForRestructuring
551000
CY2011 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
-22000
CY2011 us-gaap Restructuring Charges
RestructuringCharges
1146000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.77
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7001000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0031 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
107000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0095 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2803000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3191 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0003 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies Domestic
EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
-0.0048 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.38
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
58000 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.90
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.67
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0164 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.00 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0031 pure
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
40472
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9097000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2642000
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
95000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-117000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-8280000
CY2013 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-20000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
33684
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13076000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-8277000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
679000
CY2013 us-gaap Operating Expenses
OperatingExpenses
8375000
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
6295000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3636000
CY2013 us-gaap Adjustment For Amortization
AdjustmentForAmortization
98000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4799000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2059000
CY2013 us-gaap Depreciation
Depreciation
12000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9095000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1936000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
55000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
7998000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-35000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
212473
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4739000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
350000
CY2013 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
864000
CY2014 dei Trading Symbol
TradingSymbol
OXGN
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
679000
CY2013 oxgn Effective Income Tax Rate Reconciliation State And Local Rate Change
EffectiveIncomeTaxRateReconciliationStateAndLocalRateChange
-0.0338 pure
CY2013 oxgn Redemption Of Preferred Stock During Period Value
RedemptionOfPreferredStockDuringPeriodValue
2802000
CY2013 oxgn Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0016 pure
CY2013 oxgn Issuance Of Common Stock Under Atm
IssuanceOfCommonStockUnderAtm
1936000
CY2013 oxgn Expenses With Issuance Of Common Stock
ExpensesWithIssuanceOfCommonStock
72000
CY2013 oxgn Stock Issued During Period Value Upon Exercise Of Warrants
StockIssuedDuringPeriodValueUponExerciseOfWarrants
864000
CY2013 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P7Y7M10D
CY2013 oxgn Redemption Of Preferred Stock During Period
RedemptionOfPreferredStockDuringPeriod
2802000
CY2013 oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
35000
CY2013 oxgn Expenses With Private Placement Financing
ExpensesWithPrivatePlacementFinancing
1703000
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.87
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.20 pure
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M5D
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12151000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
521000 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y4M2D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0155 pure
CY2014 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
10417 shares
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i><u>Use of Estimates</u></i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16973000 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.01 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3066 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
33.40
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M24D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
41000 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.67
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0071 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.99 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b><i><u>Concentration of Credit Risk</u></i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company has no significant off balance sheet concentrations of credit risk. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash. The Company holds its cash and cash equivalents at one financial institution.</p> </div>
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0005 pure
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-06-30
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
295038
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3878000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
195000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-12650000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
49834
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2014 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
4711000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12647000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-12647000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
414000
CY2014 us-gaap Operating Expenses
OperatingExpenses
12650000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7408000
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
93000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23026000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Depreciation
Depreciation
16000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35194000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25682000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
206168
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5242000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
168000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9512000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
414000
CY2014 us-gaap License Costs
LicenseCosts
2600000
CY2014 oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
CY2014 oxgn Inspection Period For Product Defects
InspectionPeriodForProductDefects
P30D
CY2014 oxgn Effective Income Tax Rate Reconciliation Capital Loss Limitation
EffectiveIncomeTaxRateReconciliationCapitalLossLimitation
-0.1082 pure
CY2014 oxgn Issuance Of Common Stock In Connection With Private Placement Value
IssuanceOfCommonStockInConnectionWithPrivatePlacementValue
14822000
CY2014 oxgn Effective Income Tax Rate Reconciliation State And Local Rate Change
EffectiveIncomeTaxRateReconciliationStateAndLocalRateChange
0.0682 pure
CY2014 oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
CY2014 oxgn Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
1054625 shares
CY2014 oxgn Expenses With Issuance Of Common Stock Private Placement Exercise Of Warrant Financing
ExpensesWithIssuanceOfCommonStockPrivatePlacementExerciseOfWarrantFinancing
0
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.94
CY2014 oxgn Deferred Tax Assets Expiry Year
DeferredTaxAssetsExpiryYear
2014
CY2014 oxgn Area Of Facility Lease
AreaOfFacilityLease
5275 sqft
CY2014 oxgn Tax Credit Carryforward Beginning Expiration Year
TaxCreditCarryforwardBeginningExpirationYear
2021
CY2014 oxgn License Agreement Term
LicenseAgreementTerm
P15Y6M
CY2014 oxgn Percentage Of Distribution Revenue On Gross Margin Earned
PercentageOfDistributionRevenueOnGrossMarginEarned
0.20 pure
CY2014 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y5M27D
CY2014 oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
17000
CY2014 oxgn Expenses With Common Stock Public Offering Financing
ExpensesWithCommonStockPublicOfferingFinancing
1140000
CY2014 oxgn Issuance Of Common Stock In Connection With Public Offering Value
IssuanceOfCommonStockInConnectionWithPublicOfferingValue
10860000
CY2014 oxgn Expenses With Issuance Of Common Stock Private Placement Financing
ExpensesWithIssuanceOfCommonStockPrivatePlacementFinancing
1178000
CY2014 oxgn Issuance Of Common Stock In Connection With Private Placement Exercise Of Series B Warrants
IssuanceOfCommonStockInConnectionWithPrivatePlacementExerciseOfSeriesBWarrants
1118000
CY2014 oxgn Expenses With Issuance Of Common Stock Private Placement Exercise Of Series B Warrant Financing
ExpensesWithIssuanceOfCommonStockPrivatePlacementExerciseOfSeriesBWarrantFinancing
71000
CY2014 oxgn Issuance Of Common Stock In Connection With Public Offering Exercise Of Warrant
IssuanceOfCommonStockInConnectionWithPublicOfferingExerciseOfWarrant
2901000
CY2014 oxgn Expenses With Issuance Of Common Stock Public Offering Exercise Of Warrant Financing
ExpensesWithIssuanceOfCommonStockPublicOfferingExerciseOfWarrantFinancing
0
CY2014 oxgn Issuance Of Common Stock In Connection With Private Placement Exercise Of Warrant
IssuanceOfCommonStockInConnectionWithPrivatePlacementExerciseOfWarrant
5493000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8335000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
124000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0085 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1473000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
66.21
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M23D
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
64000 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.83
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.48
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.02 pure
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2047000
CY2012 us-gaap Restructuring Reserve Accrual Adjustment
RestructuringReserveAccrualAdjustment
15000
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
156000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-464000
CY2012 us-gaap Payments For Restructuring
PaymentsForRestructuring
678000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-8072000
CY2012 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
10000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000
CY2012 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
6000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8079000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-8079000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
511000
CY2012 us-gaap Operating Expenses
OperatingExpenses
8228000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3523000
CY2012 us-gaap Adjustment For Amortization
AdjustmentForAmortization
98000
CY2012 us-gaap Restructuring Charges
RestructuringCharges
15000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5026000
CY2012 us-gaap Depreciation
Depreciation
29000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3317000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3317000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
516257
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4690000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1352000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
511000
CY2012 oxgn Issuance Of Common Stock Under Atm
IssuanceOfCommonStockUnderAtm
1270000
CY2012 oxgn Expenses With Issuance Of Common Stock
ExpensesWithIssuanceOfCommonStock
137000
CY2012 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y7M21D
CY2012 oxgn Payments To Acquire Property Plant Equipment And Other Assets
PaymentsToAcquirePropertyPlantEquipmentAndOtherAssets
8000

Files In Submission

Name View Source Status
0001193125-15-111261-index-headers.html Edgar Link pending
0001193125-15-111261-index.html Edgar Link pending
0001193125-15-111261.txt Edgar Link pending
0001193125-15-111261-xbrl.zip Edgar Link pending
d847033d10k.htm Edgar Link pending
d847033dex141.htm Edgar Link pending
d847033dex231.htm Edgar Link pending
d847033dex311.htm Edgar Link pending
d847033dex312.htm Edgar Link pending
d847033dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
oxgn-20141231.xml Edgar Link completed
oxgn-20141231.xsd Edgar Link pending
oxgn-20141231_cal.xml Edgar Link unprocessable
oxgn-20141231_def.xml Edgar Link unprocessable
oxgn-20141231_lab.xml Edgar Link unprocessable
oxgn-20141231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending